Introduction
The renin-angiotensin-aldosterone system (RAAS) is thought to have evolved as a means to conserve salt and water in order to maintain tissue perfusion at livable levels in a very low sodium environment. Although it conferred a survival advantage in the distant past, RAAS appears to have become a liability in the high salt culture of modern times. There is an epidemic of chronic kidney disease (CKD), in part due to a dramatic increase in the prevalence of overeating in the world [1] . CKD is associated with a higher risk for cardiovascular disease, and the association is not completely accounted for by traditional risk factors, such as diabetes, hypertension, and hyperlipidemia [2] [3] [4] [5] 6 ]. Both obesity and CKD are associated with increases in activity of RAAS [7 ,8 ,9 ,10 ].
RAAS is therefore one of the most important pharmacologic targets for treating hypertension, preventing cardiovascular disease, and slowing the progression of kidney disease.
Progressive kidney disease: role of the reninangiotensin-aldosterone system CKD may affect 16.8% of the US population, and it is estimated that there will be 700 000 patients with end stage renal disease (ESRD) in America by 2015 [11 ] . Total Medicare costs for CKD and ESRD patients neared $42 billion and $20 billion in 2005, respectively, levels that certainly contribute to concerns about solvency of the federally funded Medicare program that supports most ESRD care in the United States [12] .
Significant reductions in renal mass trigger a sequence of events that results in proteinuria, glomerulosclerosis, tubulointerstitial inflammation and fibrosis, and ultimately ESRD. Angiotensin II (AgII) mediates hemodynamic effects (reviewed below) and a constellation of oxidative and inflammatory reactions that impact the growth and proliferation of mesangial cells and podocytes that contribute to progressive glomerular injury and tubulointerstitial fibrosis [13 ,14,15,16 ].
The two most important pharmacologic approaches to inhibiting the RAAS include angiotensin converting enzyme (ACE) inhibitors (ACEis) and angiotensin receptor blockers (ARBs), which affect the action of AgII on cells. Aliskerin, a renin inhibitor, has recently been approved by the US Food and Drug Administration for the treatment of hypertension [17 ] .
Evidence benefits of blockade of the renin-angiotensin-aldosterone system for cardiovascular disease and progressive renal disease
The RAAS not only modulates salt and water balance, it regulates the vascular response to injury and inflammation. In patients with heart disease and reduced left ventricular function, there is accentuated activation of the RAAS with upregulation of ACE, increased production of AgII, and increased degradation of bradykinin, all of which contribute to atherosclerosis, cardiac fibrosis and left ventricular (LV) hypertrophy [18, 19] .
ACEis and ARBs have consistently demonstrated a significant reduction in cardiovascular morbidity and mortality in multiple, large, prospective, randomized trials, and are considered standard therapy for patients with cardiovascular disease [20 ] . They appear to have a dose dependent beneficial effect on atherosclerosis progression [21] , and may also prevent the development and recurrences of atrial fibrillation [22 ,23 ] .
Control of hypertension slows the rate of progression of nephropathy in both diabetic and nondiabetic CKD, irrespective of the class of medicine, but agents that block the RAAS alter glomerular hemodynamics, reduce intraglomerular pressure and hyperfiltration, and thereby reduce proteinuria, which slows progression of CKD beyond that seen with blood pressure (BP) reduction alone [24 ,25] . The benefits of ACEi and ARB therapy in diabetic and nondiabetic kidney diseases are stronger in patients with a greater degree of proteinuria, and the effect is present over all levels of baseline glomerular filtration rate (GFR) [ Although there is scientific rationale for using agents that block RAAS for primary prevention of kidney disease in patients with early stage, nonproteinuric nondiabetic nephropathies, the evidence of benefit of RAAS inhibition is less robust, and it appears that BP control is of greater importance [35 ] .
Common clinical dilemmas
The American College of Cardiology and American Heart Association have issued practice guidelines strongly recommending ACEis as standard therapy for secondary prevention in cardiovascular patients [36] . The reasons for underuse of ACEis/ARBs in patients at risk for cardiovascular disease and or patients with kidney disease are not known, but it is likely that safety concerns contribute to underutilization. One of the frequent reasons for discontinuation of ACEis is the worry about worsening of renal function.
Worsening of kidney function with use of angiotensinconverting enzyme inhibitors/angiotensin receptor blockers: who is at risk?
Although the exact incidence of ACEi or ARB-induced acute renal insufficiency is not known, an acute increase in serum creatinine with RAAS blockade is most likely to occur in one of several situations: in patients in whom GFR is highly dependent on AgII, such as in severe highgrade bilateral renal artery stenosis or arterial stenosis in a renal transplant; in extracellular volume deletion, such as with nausea, vomiting, diarrhea, or diuretics [45] ; in patients with substantial reductions in mean arterial pressure for which renal perfusion pressure cannot be maintained, such as those with congestive heart failure [46]; in patients taking vasoconstrictor medications, such as NSAIDS, cyclooxygenase-2 inhibitors, [47, 48] or cyclosporine [49] ; and in patients with preexisting renal disease [50] .
How much of an increase in serum creatinine is tolerable with the use of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy?
The kidney displays highly efficient autoregulation such that under steady-state conditions, renal blood flow (RBF) is independent of BP over a wide range of pressures. Autoregulation functions to maintain extracellular fluid volume in spite of variations in BP, and to preserve glomerular structure [51 ,52] .
Under normal conditions, the vasoactive states of the afferent and efferent arterioles of the glomerulus are regulated via a complex interplay between systemic mechanisms (the sympathetic nervous system, natriuretic peptides, and vasopressin) paracrine factors (nitric oxide, endothelin, and prostaglandins), and the RAAS. The kidney is unique in that it has components of the RAAS in the tubular and interstitial compartments [53, 54 ] , and functional investigations and biopsy studies in humans emphasize augmentation of the intrarenal RAAS in patients with diabetic and nondiabetic kidney disease [55] [56] [57] [58] .
A reduction in nephron mass is accompanied by profound alterations in renal hemodynamics characterized by glomerular capillary hypertension, glomerular hypertrophy, and hyperfiltration [59] . AgII acts to constrict both the afferent and efferent arterioles, but has a much stronger effect on the efferent arterioles [60 ,61] . Experiments in animals and humans demonstrate that the administration of an ACEi or ARB results in a greater decrease in efferent as compared with afferent resistance, and renal plasma flow increases. An increase, a fall, or no change in GFR may result, depending on the underlying disease and status of the RAAS [62, 63] .
With loss of nephron mass autoregulation may be impaired and GFR may be more dependent on RBF [64, 65] . The presence of RAAS inhibition also prevents the glomerulus from compensating via Ag II-mediated vasoconstriction in the efferent arteriole. Experimental studies demonstrate that acute reduction in GFR with initiation of RAAS inhibition may be as high as 40% [62] .
In the clinical setting, the initial fall in GFR with RAAS inhibition (represented by an increase in serum creatinine level) is thought to be primarily functional based on current understanding of underlying renal hemodynamics. In support of this concept, Bakris and Weir [66] reviewed 12 randomized clinical trials that evaluated progression in patients with CKD and found that an increase in serum creatinine of 30% or less above baseline after initiation of ACEi or ARB therapy was common, generally occurred within 2 weeks, and was not associated with long-term harm. The initial fall in GFR associated with initiation of RAAS inhibition is usually reversible with discontinuation of ACEi or ARB therapy [67] . The NKF-KDOQI guidelines suggest that the dose of ACEi or ARB be reduced and GFR monitored more frequently if the serum creatinine increases by over 30% after initiation of RAAS inhibition [27] . There are no randomized trials that specifically address the question of what level of increase in serum creatinine should prompt withdrawal of ACEi or ARB therapy. Diuretics [45] and relative hypotension [68] appear to potentiate RAAS inhibitor-induced acute deterioration in kidney function.
My patient is about to receive contrast. Should the angiotensin-converting enzyme inhibitor or angiotensin receptor blocker be discontinued?
Contrast induced nephropathy (CIN), defined as an acute decline in renal function after the administration of radiocontrast, is the third leading cause of acute renal failure in hospitalized patients [69 ] The single most important risk factor for CIN is preexisting renal failure [70] , a situation in which RAAS blockade would likely be present. The question of whether an ACEi predisposes to CIN is not resolved. Prospective randomized controlled trials in which prophylactic use of captopril was given prior to contrast showed conflicting results [71, 72] . One observational study [73] evaluating the use of ACEis prior to contrast found ACEis to be a risk factor for CIN, whereas another found ACEis to be protective [74] . The Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) trial (see below) should help clarify whether ARBs impact the incidence of CIN.
Is there a level above which angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy is not indicated?
Post-hoc analyses of the Modification of Dietary Protein in Renal Disease Trial (MDRD) and the Ramipril Efficacy in Nephropathy (REIN) trial established that the renoprotective effects of ACEis in chronic nephropathies are independent of the severity of baseline renal function, and that ACEis slowed progression of disease even in patients with GFR of 25 ml/min/1.73 m 2 or lower [75, 76] . In a randomized prospective trial to determine whether ACE inhibition is beneficial for patients with non-diabetic advanced renal disease, 140 patients with creatinine 3.1-5.0 mg/dl were randomized to treatment with benazepril or placebo. Treatment with benazepril, as compared to placebo, resulted in a 43% overall reduction in the risk of doubling of serum creatinine, ESRD, or death [77] . It should be noted that 5% of patients were excluded during the 8-week run-in due to the development of serious hyperkalemia or increase in serum over 30% above baseline [78] .
My patient has atherosclerotic renal artery stenosis. Is it safe to administer an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker?
ACE inhibitors successfully control BP in the majority of patients with atherosclerotic renal artery stenosis (ARAS) [79] , but have the potential to relax the efferent arteriole, reduce GFR, and precipitate a functional acute renal failure. Patients with renal artery stenosis are often candidates for ACEi or ARB therapy for other indications such as diabetes, congestive heart failure, or chronic kidney disease, and RAAS inhibition may improve survival in patients with ARAS [80] .
The renal impairment that may be induced by RAAS blockade is usually rapid in onset, and recovery is equally rapid after withdrawal of the medication. The exact incidence of acute kidney injury (AKI) in patients with ARAS is unknown, but depends on the degree of and locations of stenosis [81] . A significant increase in serum creatinine can sometimes be treated with reduction or discontinuation of diuretics rather than ACEis [82] . NSAIDs should be avoided. It should also be recognized that decreases in GFR are not unique to RAAS blockade, as any medication that drops systemic BP enough to impair renal perfusion can result in deterioration in renal function. RAAS blockade-induced AKI in patients with ARAS can be severe enough to require dialysis [83] , and rarely may be permanent [84] .
The benefit of Stent Placement and Blood Pressure and Lipid-lowering for the Prevention of Progression of Renal Dysfunction caused by Atherosclerotic Ostial Stenosis of the Renal Artery (STAR) trial [85] , the CORAL trial [86] , and the Angioplasty and Stent for Renal Artery Lesions (ASTRAL) trial [87] will help clarify the optimal therapy for patients with ARAS [88] , and whether RAAS inhibition is beneficial in ARAS. Until the results of these trials are available, agents that block RAAS should be used with caution in patients with ARAS, and renal function should be monitored closely. As sodium depletion may increase the likelihood of acute AKI, it is probably advisable to reduce intensity of diuretic therapy before initiation of ACEis or ARBs, especially in patients with reduced LV function.
Are patients on combination angiotensin-converting enzyme inhibitor-angiotensin receptor blocker therapy at greater risk of developing an increase in serum creatinine?
In spite of the proven benefit of blockade of the RAAS in the management of patients with nephropathy, progression of kidney disease occurs. This may be in part due to the fact that ACE inhibitors do not completely prevent formation of AgII by alternative pathways [89] , whereas ARBs do not block all AgII type 1 receptors at clinically recommended doses [90 ,91 ] .
Although combination therapy may offer no benefit over monotherapy in patients with low albumin excretion rates and early-stage disease [92] , combination of ACEis and ARBs appears to reduce proteinuria in the short term more than either drug alone in patients with macroalbuminuric nephropathy [33 ,93] , without significant reductions in GFR [94] . Combination therapy should be used with caution in patients with LV dysfunction, as acute worsening of renal function (increased creatinine >0.5 mg/dl) was 2.2-fold more likely with the combination ACEi plus ARB than with the comparator, usually an ACEi alone in one study [95 ] .
The exact mechanisms of the antiproteinuric effects and the optimal dosages for slowing progression of disease are not known [96] . NKF-KDOQI guidelines suggest that ACEi/ARB combination therapy may be used to reduce proteinuria, but that large-scale studies are necessary to clarify the role of combination therapy in patients with CKD [27].
Conclusion
The beneficial effects of blockade of the RAAS are well established in patients at risk for cardiovascular disease and for those with diabetic and nondiabetic nephropathy.
Even patients with advanced CKD may garner protection from kidney disease progression with RAAS blockade. Overall ACEi and ARB are safe if used judiciously.
Ongoing clinical trials will help to clarify whether RAAS inhibition should be withheld prior to radiocontrast, the optimal therapy of ARAS, and the role of ACEi/ARB combination therapy in patients with progressive kidney disease.
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